How to Buy Tarsus Pharmaceuticals Stock
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
Tarsus Pharmaceuticals stock last closed at $48.51, down 1.5% from the previous day, and has increased 50.23% in one year. It has overperformed other stocks in the Biotechnology industry by 1.28 percentage points. Tarsus Pharmaceuticals stock is currently +141.56% from its 52-week low of $20.08, and -15.31% from its 52-week high of $57.28.
As of Apr 21, 2025, there are 38.38M TARS shares outstanding. The market cap of TARS is $1.86B. In the last 24 hours, 551,511 TARS shares were traded.
How to Buy Tarsus Pharmaceuticals Stock
Not sure how to invest in Tarsus Pharmaceuticals stock? Here's how.
- Choose where to buy Tarsus Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you figure out where to buy Tarsus Pharmaceuticals stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your method of payment and add your info.
- Research Tarsus Pharmaceuticals stock: The Tarsus Pharmaceuticals ticker symbol is TARS. Is Tarsus Pharmaceuticals stock a good investment? Should you buy shares of TARS? How do TARS's underlying business fundamentals look? Do top analysts think Tarsus Pharmaceuticals is a good buy? Why has TARS's stock price moved recently? (Hint: Our stock research tools can help you decide if TARS is a good stock to buy).
- Make your TARS buy order: Decide if you will purchase TARS shares at the current market price or use a limit order to purchase TARS shares at a particular price.
- Keep tabs on your TARS investment: Create a watchlist to keep tabs on your position in Tarsus Pharmaceuticals stock.
Step 1: Choose where to buy Tarsus Pharmaceuticals stock
You need an online brokerage account in order to access the NASDAQ market and buy TARS shares.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal info so you can invest in TARS today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have finished signing up on app for stock, your next step is to transfer the money for your investment:
Watch the tutorial below if you need help depositing funds into your investment account.
Step 4: Research Tarsus Pharmaceuticals stock
Once you have figured out the best place to buy Tarsus Pharmaceuticals stock, it's crucial to evaluate their stock before you buy, so you truly comprehend the risk as well as the opportunity.
Tarsus Pharmaceuticals shares data
TARS Overview
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on TARS's stock page.
Is TARS stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge TARS's true value.
Using relative valuations measures:
- TARS could be overvalued based on its P/B ratio of 8.29x, relative to Biotechnology industry P/B ratio of 4.04x
You can do additional valuation analysis on TARS's stock here.
TARS Financial Health
Pros:
- TARS has $291.38M in cash and short term investments. This is sufficient to cover its annual cash burn of $89.59M.
- Total TARS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the TARS balance sheet.
- TARS has cash burn of 89594000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the TARS balance sheet.
Cons:
- TARS has a relatively high debt to equity ratio of 0.68.
- TARS profit margin has gone up by 7.16 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy TARS stock, according to Wall Street analysts?
Out of 6 Wall Street analysts who monitor TARS, the consensus analyst rating on Tarsus Pharmaceuticals is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest TARS Analyst Forecasts
Andrea Tan, a bottom 3% analyst from Goldman Sachs maintains TARS with a hold rating and raises their TARS price target from $36.00 to $41.00, on Nov 15, 2024.
You can dig deeper into what analysts are projecting on the Tarsus Pharmaceuticals stock forecast page.
TARS Technicals
How is TARS performing as a company?
Last year, TARS revenue was $182.95M. In the past 3 year, TARS's revenue has grown by 130.22% per year. This was faster than the Biotechnology industry average of 44.31%.
You can research TARS's earnings and revenue performance here.
Latest Insiders Trades at TARS
In the last year, insiders at TARS have sold more shares than they have bought.
Bobak R. Azamian, PresidentCEO and Board Chair of TARS, was the latest TARS insider to sell. They sold $300,000.00 worth of TARS shares on Mar 24, 2025.
Research more about who owns TARS stock here.
Can I rely on TARS as an income stream?
No, Tarsus Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about TARS
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your TARS buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, place a limit order.
Click the Open button and your broker will place your order.
If you need additional assistance investing in stocks on eToro, click the how to video below:
Step 6: Keep tabs on your TARS investment
Now that you own some TARS shares, you'll want to stay up-to-date on your new stock purchase.
Start a watchlist to monitor your TARS stock.
TARS Feed
How to Buy Stock in Tarsus Pharmaceuticals
To reiterate, here are the 6 steps to buy stock in Tarsus Pharmaceuticals:
- Choose where to buy Tarsus Pharmaceuticals stock
- Create a brokerage account
- Fund your brokerage account
- Research Tarsus Pharmaceuticals stock
- Make your TARS buy order
- Keep tabs on your TARS investment
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Tarsus Pharmaceuticals, create your watchlist below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.